| **Special Charges (Details) $ in Millions**                                       | 3 Months Ended | 12 Months Ended |
|-----------------------------------------------------------------------------------|----------------|-----------------|
||
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Number of operating divisions | division                                          |           |            |   |   | 2 |
| Litigation settlement gains                                                       | $ 19           |            |   |   |   |
| Loss (benefit) contingency in period                                              | $ 2            |            |   |   |   |
| Number of legal settlements | settlement                                          | 2              |            |   |   |   |
| Restructuring-related costs                                                       | $ 2            |            |   |   |   |
| Field Action Costs | Operating Expense                                            |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Litigation charges                                                                | 3              |            | $ 5 |   |   |
| Field Action Costs, Salvaged Inventory | Cost of sales                            |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Loss (benefit) contingency in period                                              |           |            | (2) |   |   |
| March 2010 Securities Class Action                                                |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Insurance recoveries                                                              |           |            | $ 10 |   |   |
| 2016 Initiatives                                                                  |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   | 24             | $ 34            |   |   |   |
| 2016 Initiatives | Operating Expense                                              |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   | 20             |            |   | $ 22 |   |
| 2016 Initiatives | Cost of sales                                                  |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   | 4              |            |   | 12 |   |
| Manufacturing and Supply Chain Optimization Plan                                  |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   | 1              |            |   | 78 |   |
| Manufacturing and Supply Chain Optimization Plan | Operating Expense              |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   |           |            |   | 49 |   |
| Manufacturing and Supply Chain Optimization Plan | Cost of sales                  |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   | 1              |            |   | 29 |   |
| 2012 Business Realignment Restructuring Plan                                      |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   |           |            |   | 14 |   |
| 2012 Business Realignment Restructuring Plan | Operating Expense                  |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   |           |            |   | 9 |   |
| 2012 Business Realignment Restructuring Plan | Cost of sales                      |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Special charges                                                                   | (2)            |            |   | $ 5 |   |
| Minimum | 2016 Initiatives                                                        |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Expected cost remaining                                                           | 30             |            |   |   |   |
| Maximum | 2016 Initiatives                                                        |           |            |   |   |   |
| **Purchased In-Process Research And Development (IPR&D) And Special Charges** |           |            |   |   |   |
| Expected cost remaining                                                           | $ 35           |            |   |   |   |

| X                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Number of Legal Settlements
+ References
No definition available.
+ Details**Name:**stj_NumberofLegalSettlements**Namespace Prefix:**stj_**Data Type:**xbrli:integerItemType**Balance Type:**na**Period Type:**duration |
| X                                                                                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Number of Operating Divisions
+ References
No definition available.
+ Details**Name:**stj_NumberofOperatingDivisions**Namespace Prefix:**stj_**Data Type:**xbrli:integerItemType**Balance Type:**na**Period Type:**duration |
| X                                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Purchased In-Process Research And Development (IPR&D) And Special Charges [Line Items]
+ References
No definition available.
+ Details**Name:**stj_PurchasedInProcessResearchAndDevelopmentIprdAndSpecialChargesLineItems**Namespace Prefix:**stj_**Data Type:**xbrli:stringItemType**Balance Type:**na**Period Type:**duration |
| X                                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Includes costs associated with cost of sales expenses and operating expenses that are unusual or infrequent in occurrence (such as restructuring, remediation, impairment charges and certain litigation charges).
+ References
No definition available.
+ Details**Name:**stj_TotalSpecialCharges**Namespace Prefix:**stj_**Data Type:**xbrli:monetaryItemType**Balance Type:**debit**Period Type:**duration |
| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349
+ Details**Name:**us-gaap_GainLossRelatedToLitigationSettlement**Namespace Prefix:**us-gaap_**Data Type:**xbrli:monetaryItemType**Balance Type:**credit**Period Type:**duration |
| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details**Name:**us-gaap_LegalFees**Namespace Prefix:**us-gaap_**Data Type:**xbrli:monetaryItemType**Balance Type:**debit**Period Type:**duration |
| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349
+ Details**Name:**us-gaap_LossContingencyLossInPeriod**Namespace Prefix:**us-gaap_**Data Type:**xbrli:monetaryItemType**Balance Type:**debit**Period Type:**duration |
| X                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Amount of expected cost remaining for the specified restructuring cost.
+ References
No definition available.
+ Details**Name:**us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1**Namespace Prefix:**us-gaap_**Data Type:**xbrli:monetaryItemType**Balance Type:**debit**Period Type:**instant |
| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section P -Subsection 3, 4
+ Details**Name:**us-gaap_RestructuringAndRelatedCostIncurredCost**Namespace Prefix:**us-gaap_**Data Type:**xbrli:monetaryItemType**Balance Type:**debit**Period Type:**duration |
| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
The gross income statement effect of insurance proceeds for each material event or transaction (that would not reasonably be expected to recur in the foreseeable future) that possesses a high degree of abnormality and are clearly unrelated to, or incidentally related to, the ordinary and typical activities of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6365513&loc=d3e15138-107781
+ Details**Name:**us-gaap_UnusualOrInfrequentItemInsuranceProceeds**Namespace Prefix:**us-gaap_**Data Type:**xbrli:monetaryItemType**Balance Type:**credit**Period Type:**duration |
| X                                                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_LossContingenciesByNatureOfContingencyAxis=stj_FieldActionCostsMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_LossContingenciesByNatureOfContingencyAxis=stj_FieldActionCostsSalvagedInventoryMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_LitigationCaseAxis=stj_March2010SecuritiesClassActionMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_RestructuringPlanAxis=stj_A2016InitiativesMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_RestructuringPlanAxis=stj_ManufandSupplyOptimizationPlanMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_RestructuringPlanAxis=stj_A2012BusinessRealignmentRestructuringPlanMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_RangeAxis=us-gaap_MinimumMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |
| X                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**us-gaap_RangeAxis=us-gaap_MaximumMember**Namespace Prefix:****Data Type:**na**Balance Type:****Period Type:** |